Delivery Order SPE2DR25D3501-SPE2DR26FM2GH
- Not listed
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,186,420 units of Ganirelix Acetate 250 mcg/0.5 mL. The $4,320.00 order has a completion date of December 28, 2023. Amerisourcebergen Drug Corp is a prime contractor that has previously received numerous federal awards from DLA Troop Support Medical to supply pharmaceuticals, medical supplies, and...
- The Defense Logistics Agency awarded a delivery order valued at $3,152.51 to AmerisourceBergen Drug Corp for the supply of Ganirelix Acetate 250 mcg/0.5 mL injection on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-competitive, firm fixed-price delivery order will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, as a firm fixed price delivery order. The $6,560.18 contract is for the delivery of the pharmaceutical product Ganirelix Acetate 250 mcg/0.5 mL, with a completion date of April 11, 2024. Amerisourcebergen Drug Corp has received numerous past contract awards from DLA Troop Support Medical to supply a variety of...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,058.04, is for the delivery of the drug Ganirelix Acetate 250 MCG/0.5 ML 0.5ML. It has an ultimate completion date of December 11, 2024. This contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of GANIRELIX ACET 250 MCG/0.5 ML 0.5ML, a pharmaceutical product. The contract has a ceiling value of $5,566.28 and a completion date of March 18, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of a specific medication - Ganirelix Acetate 250 mcg/0.5 ml. The contract, valued at $7,291.08, is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical, which serves as the primary logistics provider for the Department of Defense (DoD). The contract has an ultimate completion date of April 16, 2024. Amerisourcebergen holds a larger Indefinite...
- The U.S. Defense Logistics Agency Troop Support Medical awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide the pharmaceutical product GANIRELIX ACET 250 MCG/0.5 ML 0.5ML. The $39,504.33 order is to be completed by January 24, 2024. AmerisourceBergen Drug Corp is a for-profit organization that has previously received multiple federal contract awards from the Defense Logistics Agency to supply pharmaceuticals, medical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $38,412.50 for GONAL-F RFF Redi-Ject 900 Unit 1.44ML, a pharmaceutical product, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be...
- The Defense Logistics Agency awarded a $28,981.54 delivery order to AmerisourceBergen Drug Corp for GONAL-F RFF Redi-Ject 900 Unit 1.44ML, a pharmaceutical product for federal medical supply needs. This competitively awarded, firm fixed price delivery order is scheduled for completion by December 8, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the vendor's demonstrated...
- The Defense Logistics Agency awarded a $16,273.78 delivery order to AmerisourceBergen Drug Corp for GONAL-F RFF Redi-Ject 900 Unit 1.44ML, a pharmaceutical product, with an ultimate completion date of December 16, 2025. This is a firm fixed price, non-set-aside contract performed at the awardee's Conshohocken, Pennsylvania location. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- SPE2DR25D3501Indefinite Delivery Contract
- SPE2DR25D3501-SPE2DR26FM2GHDelivery Order
The Defense Logistics Agency awarded a $5,573.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 13, 2026, for the supply of Ganirelix Acetate 250 micrograms/0.5 milliliters. This is a non-set-aside competitive award with an ultimate completion date of January 14, 2026. The product will be delivered to the contracting location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order represents a task order issued under AmerisourceBergen's parent company, Cencora, Inc.'s, significant Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 and extending through December 2031. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal military and healthcare systems, leveraging its comprehensive Indefinite Delivery Contract vehicle to supply a diverse range of medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The company's federal contract portfolio demonstrates consistent capability to fulfill competitive procurement requirements for essential pharmaceutical products supporting military treatment facilities, veterans' healthcare programs, and other government medical institutions worldwide. This transaction exemplifies the company's operational efficiency in executing time-sensitive medical supply orders within the federal procurement framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.6k | 1/12/26 |